{"id":"NCT03293485","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)","officialTitle":"A Phase III Non-randomized, Non-controlled, Open Label Clinical Trial to Study the Safety and Efficacy of Imipenem/Cilastatin/Relebactam (IMI/REL [MK-7655A]) in Japanese Subjects With Complicated Intra-Abdominal Infection (cIAI) or Complicated Urinary Tract Infection (cUTI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-04","primaryCompletion":"2018-09-14","completion":"2018-09-14","firstPosted":"2017-09-26","resultsPosted":"2019-09-17","lastUpdate":"2021-02-12"},"enrollment":83,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Complicated Intra-abdominal Infection","Complicated Urinary Tract Infection"],"interventions":[{"type":"DRUG","name":"Imipenem+Cilastatin/Relebactam","otherNames":["IMI/REL","MK-7655A"]}],"arms":[{"label":"Imipenem+Cilastatin/Relebactam","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL, MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or complicated urinary tract infection (cUTI).","primaryOutcome":{"measure":"Percentage of Participants Experiencing â‰¥1 Adverse Events (AE)","timeFrame":"Up to 28 days","effectByArm":[{"arm":"cIAI/cUTI","deltaMin":74.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":29,"countries":["Japan"]},"refs":{"pmids":["33191112"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":81},"commonTop":["Diarrhoea","Nausea","Nasopharyngitis"]}}